[1] Su W, Ruan YZ, Li T, Du X, Jiang JW, Li RZ. Characteristics of rifampicin-resistant tuberculosis detection in China, 2015-2019. Infect Dis Poverty 2021;10(1):99. http://dx.doi.org/10.1186/s40249-021-00883-8CrossRef
[2] Wang N, Li T, Du X, Li Y, Sun MM, Huan ST, et al. Effectiveness of the integrated TB surveillance system - China, 2018-2019. China CDC Wkly 2020;2(12):190 − 3. http://dx.doi.org/10.46234/ccdcw2020.050CrossRef
[3] Zhao YL, Xu SF, Wang LX, Chin DP, Wang SF, Jiang GL, et al. National survey of drug-resistant tuberculosis in China. N Engl J Med 2012;366(23):2161 − 70. http://dx.doi.org/10.1056/NEJMoa1108789CrossRef
[4] Lu P, Liu Q, Martinez L, Yang HT, Lu W, Ding XY, et al. Time to sputum culture conversion and treatment outcome of patients with multidrug-resistant tuberculosis: a prospective cohort study from urban China. Eur Respir J 2017;49(3):1601558. http://dx.doi.org/10.1183/13993003.01558-2016CrossRef
[5] Heyckendorf J, Georghiou SB, Frahm N, Heinrich N, Kontsevaya I, Reimann M, et al. Tuberculosis treatment monitoring and outcome measures: new interest and new strategies. Clin Microbiol Rev 2022;35(3):e0022721. http://dx.doi.org/10.1128/cmr.00227-21CrossRef